Ipsen Confirmed as OBN Corporate Patron


Sign up online today & collaborate

or click here to find out more

Ipsen Confirmed as OBN Corporate Patron


Abingdon, UK: OBN – the membership organisation supporting the UK’s innovative life sciences companies is pleased to announce today that Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical company, has become a Corporate Patron of OBN.

Through their sponsorship of OBN’s activities, thirteen best-in-class companies are now actively supporting the UK life sciences sector. As Corporate Patron, Ipsen joins Corporate Sponsors, MEPC Milton Park, Fieldfisher, James Cowper Kreston LLP, World Courier, Arthur J Gallagher, PCI, J A Kemp, EY, Penningtons Manches LLP, Horton International, Fisher Scientific, and Citigate Dewe Rogerson.

Dr John Harris, CEO of OBN, said: “We’re thrilled to be working with Ipsen and really excited that they have agreed to come on board as a Corporate Patron. Ipsen’s support is a ringing endorsement of the work that OBN does in nurturing and developing the innovative Life Sciences sector. There’s an incredibly strong alignment between our two organisations’ commitments to promoting and developing activities in the region and we look forward to working closely with Ipsen to help them achieve their ambition of becoming a leader in specialty healthcare solutions for targeted debilitating diseases.”

Ipsen will support OBN in meeting the aims of its initiative: to provide networking, partnering, group purchasing services, investor introductions, cluster consultancy and better communication across the life sciences industry.

John Chaddock, Vice President Neurology and Site Head of Ipsen Bioinnovation, commented: “Ipsen has been a member of OBN for a number of years and has seen the organisation grow and develop its scope of support for the Life Sciences sector.  In addition to its increasing presence in the UK in terms of operations and manufacturing, Ipsen will further expand its R&D capabilities with the opening of a new larger R&D centre in Oxford at Milton Park campus, dedicated to innovative neurotoxin research, in the months to come.  Improving the lives of patients is what drives the whole Ipsen team and therefore supporting OBN as a Corporate Patron is an important part of engagement with the local and UK life sciences industry as Ipsen searches for innovative solutions for the patient.”

Company Website

© Catalyst Innovation Portal 2019